Medico Remedies Limited has informed the Exchange regarding Resignation of Hasan Bohra as Company Secretary & Compliance Officer of the company w.e.f. August 08, 2025.
MEDICO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medico Remedies has informed the exchange that Mr. Hasan Bohra has resigned as Company Secretary, Compliance Officer, and Key Managerial Personnel effective August 8, 2025, citing other professional commitments. In the same board meeting, the company also approved its Q1 FY26 (quarter ended June 30, 2025) standalone financial results. Revenue from operations rose to Rs. 3,825.15 lakhs from Rs. 3,079.81 lakhs in Q1 FY25, a growth of about 24% year-on-year. Net profit for the quarter stood at Rs. 181.83 lakhs versus Rs. 157.89 lakhs last year, with basic EPS of Rs. 0.22. The company remains heavily export-oriented, with overseas sales of Rs. 3,245.01 lakhs against domestic sales of Rs. 539.65 lakhs. Statutory auditors V J Shah & Co issued an unmodified limited review report on the results.
The KMP-level resignation is a routine governance change with the stated reason being personal professional commitments and is unlikely to materially affect operations. The Q1 results show healthy revenue growth and stable margins, which is mildly positive for shareholders.